Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

24.18 -0.19 (-0.78%)
Streaming Delayed Price Updated: 11:43 AM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - A High Growth Momentum Stock with Strong Technical Setup
CATALYST PHARMACEUTICALS (CPRX) shows strong earnings momentum and a bullish technical setup, making it a candidate for high-growth investors. 
Via Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - A Strong Candidate for Affordable Growth Investors
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, solid profitability, and reasonable valuation, making it an attractive option for investors seeking affordable growth stocks in biotech. 
Via Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a candidate for high growth investors. Here's why.
A fundamental and technical analysis of (NASDAQ:CPRX): Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is Poised for High Growth. 
Via Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender for CANSLIM Investors
CATALYST PHARMACEUTICALS (CPRX) meets CANSLIM criteria with strong earnings growth, high relative strength, and solid fundamentals. A top pick for growth investors. 
Via Chartmill
Should you consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) for growth investing?
A fundamental analysis of (NASDAQ:CPRX): CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) showing high EPS and FCF growth while beating expectations 
Via Chartmill
Earnings Scheduled For May 7, 2025
Via Benzinga
Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Does CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) meet the Minervini criteria?
A fundamental and technical analysis of (NASDAQ:CPRX): Why the high growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
Exploring CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s quality characteristics.
A fundamental analysis of (NASDAQ:CPRX): Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) Deserves Consideration as a Quality Investment. 
Via Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) – A Strong Candidate for CAN SLIM Investors
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) – A Strong Candidate for CAN SLIM Investors 
Via Chartmill
Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) on the Verge of a Major Breakout as a Strong Growth Stock?
Based on fundamental and technical analysis of NASDAQ:CPRX we ask: Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) Is a Standout High-Growth Stock in a Consolidation Phase. 
Via Chartmill
Investors should take note of CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), a growth stock that remains attractively priced.
CATALYST PHARMACEUTICALS INC was identified as an affordable growth stock. NASDAQ:CPRX is showing great growth, but also scores well on profitability. At the same time it seems to be priced... 
Via Chartmill
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025
The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock.
A fundamental analysis of (NASDAQ:CPRX): Delving into CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s Growth Prospects. 
Via Chartmill
Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) a Fit for high Growth Investing Strategies?
A fundamental and technical analysis of (NASDAQ:CPRX): Why the high growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX). 
Via Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a candidate for growth investors. Here's why.
A fundamental analysis of (NASDAQ:CPRX): CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a candidate for growth investors. Here's why. 
Via Chartmill
Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Why Mark Minervini may look into CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)
A fundamental and technical analysis of (NASDAQ:CPRX): Should you consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) for high growth investing? 
Via Chartmill
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday
Via The Motley Fool
Topics Economy Government World Trade
Exposures Economy Political Tariff
Why the growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX).
A fundamental analysis of (NASDAQ:CPRX): Should you consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) for growth investing? 
Via Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is showing decent growth, but is still valued reasonably.
CATALYST PHARMACEUTICALS INC could be undervalued. NASDAQ:CPRX is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced. 
Via Chartmill
Should you consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) for growth investing?
A fundamental analysis of (NASDAQ:CPRX): Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock. 
Via Chartmill
Celsius, Lucid And Signet Are Among Top 10 Mid-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?
Top performers last week: DGNX (108.29%), NEXT (25.07%), CELH (21.60%), SIG (21.08%), NFE (20.63%), MRP (16.61%), ARQT (16.35%), LCID (15.79%), CPRX (15.27%), STNE (14.20%). Are they in your... 
Via Benzinga
For those who appreciate value investing, CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a compelling option with its solid fundamentals.
Uncover the potential of CATALYST PHARMACEUTICALS INC, an undervalued stock. NASDAQ:CPRX maintains a strong financial position and offers an appealing valuation. 
Via Chartmill
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a CANSLIM stock.
A fundamental analysis of (NASDAQ:CPRX): Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) a Fit for Growth Investing Strategies? 
Via Chartmill
Looking for growth without the hefty price tag? Consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX).
CATALYST PHARMACEUTICALS INC was identified as an affordable growth stock. NASDAQ:CPRX is showing great growth, but also scores well on profitability. At the same time it seems to be priced... 
Via Chartmill
Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) on the Verge of a Major Breakout as a Strong Growth Stock?
Based on a technical and fundamental analysis of NASDAQ:CPRX we are exploring the Growth Potential of CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) as It Nears a Breakout. 
Via Chartmill
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) suited for growth investing?
A fundamental analysis of (NASDAQ:CPRX): Is CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) suited for growth investing? 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.